Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.65 |
| ▸ | MMP3 | P08254 | 16/20 | 0.65 |
| ▸ | MMP7 | P09237 | 15/20 | 0.65 |
| ▸ | MMP1 | P03956 | 14/20 | 0.64 |
| ▸ | MMP8 | P22894 | 2/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
| ▸ | MMP14 | P50281 | 1/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | FCER2 | P06734 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696746 | 0.89 | MMP2 (0.70) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL7883062 | 0.89 | MMP2 (0.70) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4422495 | 0.89 | MMP2 (0.70) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL7883057 | 0.89 | MMP2 (0.70) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4422794 | 0.88 | MMP2 (0.69) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4431005 | 0.86 | MMP2 (0.66) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4428170 | 0.83 | MMP2 (0.81) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL7654835 | 0.82 | MMP2 (0.59) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4421723 | 0.81 | MMP2 (0.78) | MMP2MMP3MMP7MMP1MMP8 | |
| SCHEMBL4431974 | 0.81 | MMP2 (0.78) | MMP2MMP3MMP7MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | claimed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | MMP2 507/4885MMP3 455/4885MMP7 814/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | MMP2 507/4885MMP3 455/4885MMP7 814/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | MMP2 507/4885MMP3 455/4885MMP7 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.